[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486456":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":46,"centralContacts":50,"locations":59,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of Aberdeen","OTHER",[8,15,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Development Group 1 (N = 10) (Development Phase)",null,"Development group participants (N = 10) will undergo 1 magnetic resonance imaging (MRI) sessions. Before and after their MRI scan participants will be given a pinprick blood sugar test.",[13,14],"Other: Magnetic Resonance Imaging (MRI)","Other: Blood Glucose Assessment",{"label":16,"type":10,"description":17,"interventionNames":18},"Patients (N = 20) (Clinical Phase)","Patients (N = 20) will attend 2 visits up to 1 week apart. Patients will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.\n\nVisit 1: Patients will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:\n\nVisit 2: Patients will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments.",[13,14,19,20],"Other: Positron Emission Tomography (PET)","Other: Cognitive Assessment",{"label":22,"type":10,"description":23,"interventionNames":24},"Healthy Controls (N = 20) (Clinical Phase)","Healthy controls (N = 20) will attend 2 visits up to 1 week apart. Healthy controls will be age matched (+\u002F- 3 years) and sex matched to the patient group. Healthy controls will be asked to have a no-sugar diet and take no exercise for 24 hours before each visit and to avoid eating 6 hours before scan.\n\nVisit 1: Healthy Controls will undergo a positron emission tomography (PET) assessment. Before and after their PET assessment patients will be given a pinprick blood sugar test. PET assessment:\n\nVisit 2: Healthy Controls will undergo MRI assessment. Before and after their MRI scan patients will be given a pinprick blood sugar test. Healthy controls will complete cognitive assessments.",[13,14,19,20],{"label":26,"type":10,"description":27,"interventionNames":28},"Development Group 2 (N = 10) (Development Phase)","To investigate the repeatability of MRI assessment, 10 development phase healthy volunteers will be recruited to undergo two repeated study assessments. The second visit will be between 7 and 14 days after their first visit. The second repeated study assessment will follow the same procedure as the first visit, consisting of blood glucose assessment and MRI assessment. Participants will be advised to fast from mid-night and avoid eating breakfast.",[13,14],[30,34,38,42],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Magnetic Resonance Imaging (MRI)","Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.",[9,26,22,16],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Blood Glucose Assessment","A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg\u002Fdl (3.9-6 mmol\u002FL). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.",[9,26,22,16],{"type":6,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Positron Emission Tomography (PET)","Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.",[22,16],{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"Cognitive Assessment","Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.",[22,16],[47],{"name":48,"affiliation":5,"role":49},"Gordon Waiter, PhD","STUDY_CHAIR",[51,55],{"name":48,"role":52,"phone":53,"phoneExt":10,"email":54},"CONTACT","+44 (0)1224 438356","g.waiter@abdn.ac.uk",{"name":56,"role":52,"phone":57,"phoneExt":10,"email":58},"Nicholas Senn de Vries, PhD","+44 (0)1224 438352","nicholas.senn2@abdn.ac.uk",[60],{"facility":5,"status":61,"city":62,"state":10,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Aberdeen","AB24 3FX","United Kingdom","UK",{"type":67,"coordinates":68},"Point",[69,70],-2.09814,57.14369,{"lat":70,"lon":69},[73,74],{"name":48,"role":52,"phone":53,"phoneExt":10,"email":54},{"name":56,"role":52,"phone":57,"phoneExt":10,"email":58},{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[78],{"name":79,"class":80},"NHS Grampian","OTHER_GOV","100486456","detecting-early-alzheimers-using-mr-100486456",false,"NCT05614310","Detecting Early Alzheimer's Using MR","Early Detection Of Alzheimer's Disease With GlucoCEST MRI: A Feasibility Study.","DREAMER","Inclusion Criteria:\n\nDevelopment phase:\n\nControls (development group) must:\n\n* be \\> 18 years\n* consent to the study\n* not report problems with memory.\n\nClinical phase\n\nPatients must:\n\n* be ≥ 65 years,\n* able to provide informed consent to the study\n* have been clinically diagnosed with AD by the mental health team.\n\nControls must:\n\n* be ≥ 65 years\n* able to provide consent to the study\n* have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE)\n* not report problems with memory.\n\nExclusion Criteria:\n\nSubjects will not be considered if they:\n\n* have a history of diabetes,\n* have history of a major stroke (mini-stroke\u002FTransient Ischaemic Attacks or lacunar stroke are acceptable),\n* have contra-indications to MRI scanning such as implantable cardiac devices\n* have family history in AD, to exclude possible gene mutations associated with AD\n* have advanced AD who lack the capacity to consent.\n* Are pregnant (for developmental phase)\n* are unable to read or speak English",true,"ALL","18 Years",{"count":93,"type":94},60,"ESTIMATED","OBSERVATIONAL","Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 10% of individuals aged ≥ 65. Most available treatments aim at controlling symptoms at an early stage rather than providing a cure. Therefore, an accurate and early diagnosis of AD with appropriate management will slow the progression of the condition. Reduced cerebral glucose levels have been observed in patients with early AD. Glucose hypometabolism can be assessed by administering a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG), and imaging with PET (positron emission tomography). The high cost and limited availability of PET-CT (PET - computed tomography) still hamper its general clinical application. Moreover, the use of radioactive tracers in combination with the additional ionizing radiation of CT is not suitable for repeated measurements. Therefore, currently, the provisional diagnosis of AD is still based on the combination of clinical history, neurological examination, cognitive testing over a period of time, and structural neuroimaging. This has major time and resource implications.\n\nA radically different and highly innovative means for imaging glucose with magnetic resonance imaging (MRI) has now been established, exploiting the interaction between hydroxyl protons in glucose and the protons in water; the method is termed glucose Chemical Exchange Saturation Transfer (glucoCEST). GlucoCEST MRI is a method that has no reliance on radiolabelled glucose analogues and could become widely implemented in clinic practice. We therefore aim to investigate the potential of glucoCEST MRI in Alzheimer's disease.",[98],"Alzheimer Disease",[31,100],"Glucose Chemical Exchange Saturation Transfer (CEST)","2025-03-25",{"date":103,"type":104},"2025-03-30","ACTUAL",{"date":106,"type":104},"2022-11-15",{"date":108,"type":94},"2025-12-31",{"name":5,"class":6},1]